{"id":65299,"date":"2026-05-14T14:28:42","date_gmt":"2026-05-14T06:28:42","guid":{"rendered":"https:\/\/flcube.com\/?p=65299"},"modified":"2026-05-14T14:28:43","modified_gmt":"2026-05-14T06:28:43","slug":"tennor-therapeutics-raises-71m-in-hong-kong-ipo-antimicrobial-pipeline-targets-h-pylori-and-implant-associated-infections","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65299","title":{"rendered":"TenNor Therapeutics Raises $71M in Hong Kong IPO \u2013 Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections"},"content":{"rendered":"\n<p><strong>TenNor Therapeutics (Suzhou) Limited<\/strong> completed its <strong>initial public offering (IPO)<\/strong> on the <strong>Hong Kong Stock Exchange<\/strong>, pricing <strong>8,280,550 shares<\/strong> at <strong>HKD 75.7 (USD 9.66)<\/strong> per share. The company expects to generate <strong>net proceeds of HKD 557.8 million (USD 71.22 million)<\/strong> to advance its antimicrobial pipeline toward commercialization.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-ipo-financial-details-amp-capital-allocation\">IPO Financial Details &amp; Capital Allocation<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Amount<\/th><th>Allocation Purpose<\/th><\/tr><\/thead><tbody><tr><td><strong>Shares Offered<\/strong><\/td><td>8,280,550<\/td><td>Primary offering<\/td><\/tr><tr><td><strong>Price per Share<\/strong><\/td><td>HKD 75.7 (USD 9.66)<\/td><td>IPO pricing<\/td><\/tr><tr><td><strong>Net Proceeds<\/strong><\/td><td>HKD 557.8M (USD 71.22M)<\/td><td>R&amp;D, registration, and commercialization of core products<\/td><\/tr><tr><td><\/td><td><\/td><td>Construction of proprietary manufacturing facility<\/td><\/tr><tr><td><\/td><td><\/td><td>General corporate operations<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-company-profile-amp-strategic-focus\">Company Profile &amp; Strategic Focus<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Founded:<\/strong> 2013<\/li>\n\n\n\n<li><strong>Stage:<\/strong> Approaching commercialization<\/li>\n\n\n\n<li><strong>Therapeutic Focus:<\/strong> Bacterial infections and bacteria metabolism-related diseases<\/li>\n\n\n\n<li><strong>Mission:<\/strong> Address unmet medical needs through differentiated innovative drug products<\/li>\n\n\n\n<li><strong>Pipeline:<\/strong> Seven innovative programs with two core assets advancing through clinical development<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-core-pipeline-assets\">Core Pipeline Assets<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-rifasutenizol-tnp-2198-new-molecular-entity-nme\">Rifasutenizol (TNP-2198) \u2013 New Molecular Entity (NME)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Indication 1:<\/strong> <strong>H. pylori infection<\/strong> \u2013 Phase III trials ongoing in <strong>China and United States<\/strong><\/li>\n\n\n\n<li>Combination therapy with amoxicillin and proton pump inhibitor (PPI)<\/li>\n\n\n\n<li><strong>Indication 2:<\/strong> <strong>Bacterial vaginosis<\/strong> \u2013 Monotherapy trials in <strong>China<\/strong><\/li>\n\n\n\n<li><strong>Indication 3:<\/strong> <strong>Clostridioides difficile infection<\/strong> \u2013 Monotherapy trials in <strong>China<\/strong><\/li>\n\n\n\n<li><strong>Status:<\/strong> Most advanced asset with multiple late-stage clinical programs<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-tnp-2092-triple-target-antimicrobial\">TNP-2092 \u2013 Triple-Target Antimicrobial<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Simultaneously targets three bacterial pathways for enhanced efficacy<\/li>\n\n\n\n<li><strong>Target Indications:<\/strong> <strong>Implant-associated bacterial infections<\/strong> including:<\/li>\n\n\n\n<li>Acute bacterial skin and skin structure infections (ABSSSI)<\/li>\n\n\n\n<li>Prosthetic joint infections (PJI)<\/li>\n\n\n\n<li>Left ventricular assist device infections (LVADI)<\/li>\n\n\n\n<li>Central line-associated bloodstream infections (CRBSI)<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Addresses growing challenge of device-related infections in aging populations<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-investment-rationale\">Market Context &amp; Investment Rationale<\/h2>\n\n\n\n<p><strong>Antimicrobial Resistance Crisis:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>WHO identifies antimicrobial resistance as one of the top 10 global public health threats<\/li>\n\n\n\n<li>Limited new antibiotic approvals over the past decade despite increasing resistance<\/li>\n\n\n\n<li>High unmet need in both community-acquired (H. pylori) and hospital-acquired (implant-associated) infections<\/li>\n<\/ul>\n\n\n\n<p><strong>Commercial Opportunity:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>H. pylori market:<\/strong> Affects ~50% of global population; standard therapies facing increasing resistance rates<\/li>\n\n\n\n<li><strong>Implant-associated infections:<\/strong> Growing market driven by aging population and increased medical device usage<\/li>\n\n\n\n<li><strong>Regulatory incentives:<\/strong> QIDP designation, priority review vouchers, and extended exclusivity periods available<\/li>\n<\/ul>\n\n\n\n<p><strong>Strategic Advantages:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual-market development:<\/strong> Simultaneous clinical programs in China and U.S. de-risk regulatory pathways<\/li>\n\n\n\n<li><strong>Manufacturing control:<\/strong> Proceeds allocated to proprietary facility ensures supply chain security<\/li>\n\n\n\n<li><strong>Differentiated mechanisms:<\/strong> Novel targets address resistance concerns with existing antibiotics<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-post-ipo-development-strategy\">Post-IPO Development Strategy<\/h2>\n\n\n\n<p>The IPO proceeds will accelerate TenNor&#8217;s transition from clinical-stage to commercial-stage biotech, with rifasutenizol potentially reaching market within 2-3 years if current trials succeed. The company&#8217;s focus on both community and hospital settings provides diversified revenue streams and reduces dependence on single indication success.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, commercial expectations, and use of IPO proceeds. Actual results may differ due to risks including clinical trial outcomes, regulatory requirements, competitive dynamics, market conditions, and execution challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026051400014_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026051400014_c.\"><\/object><a id=\"wp-block-file--media-9680bd3e-637e-48ab-9aeb-6449d65f25f1\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026051400014_c.pdf\">2026051400014_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026051400014_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-9680bd3e-637e-48ab-9aeb-6449d65f25f1\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>TenNor Therapeutics (Suzhou) Limited completed its initial public offering (IPO) on the Hong Kong Stock&#8230;<\/p>\n","protected":false},"author":1,"featured_media":65301,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[72,2192],"class_list":["post-65299","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-ipo","tag-tennor-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>TenNor Therapeutics Raises $71M in Hong Kong IPO \u2013 Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"TenNor Therapeutics (Suzhou) Limited completed its initial public offering (IPO) on the Hong Kong Stock Exchange, pricing 8,280,550 shares at HKD 75.7 (USD 9.66) per share. The company expects to generate net proceeds of HKD 557.8 million (USD 71.22 million) to advance its antimicrobial pipeline toward commercialization.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65299\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TenNor Therapeutics Raises $71M in Hong Kong IPO \u2013 Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections\" \/>\n<meta property=\"og:description\" content=\"TenNor Therapeutics (Suzhou) Limited completed its initial public offering (IPO) on the Hong Kong Stock Exchange, pricing 8,280,550 shares at HKD 75.7 (USD 9.66) per share. The company expects to generate net proceeds of HKD 557.8 million (USD 71.22 million) to advance its antimicrobial pipeline toward commercialization.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65299\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-14T06:28:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-14T06:28:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1403.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65299#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65299\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"TenNor Therapeutics Raises $71M in Hong Kong IPO \u2013 Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections\",\"datePublished\":\"2026-05-14T06:28:42+00:00\",\"dateModified\":\"2026-05-14T06:28:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65299\"},\"wordCount\":463,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65299#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1403.webp\",\"keywords\":[\"IPO\",\"TenNor Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65299#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65299\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65299\",\"name\":\"TenNor Therapeutics Raises $71M in Hong Kong IPO \u2013 Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65299#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65299#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1403.webp\",\"datePublished\":\"2026-05-14T06:28:42+00:00\",\"dateModified\":\"2026-05-14T06:28:43+00:00\",\"description\":\"TenNor Therapeutics (Suzhou) Limited completed its initial public offering (IPO) on the Hong Kong Stock Exchange, pricing 8,280,550 shares at HKD 75.7 (USD 9.66) per share. The company expects to generate net proceeds of HKD 557.8 million (USD 71.22 million) to advance its antimicrobial pipeline toward commercialization.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65299#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65299\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65299#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1403.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1403.webp\",\"width\":1080,\"height\":608,\"caption\":\"TenNor Therapeutics Raises $71M in Hong Kong IPO \u2013 Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65299#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TenNor Therapeutics Raises $71M in Hong Kong IPO \u2013 Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"TenNor Therapeutics Raises $71M in Hong Kong IPO \u2013 Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections - Insight, China&#039;s Pharmaceutical Industry","description":"TenNor Therapeutics (Suzhou) Limited completed its initial public offering (IPO) on the Hong Kong Stock Exchange, pricing 8,280,550 shares at HKD 75.7 (USD 9.66) per share. The company expects to generate net proceeds of HKD 557.8 million (USD 71.22 million) to advance its antimicrobial pipeline toward commercialization.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65299","og_locale":"en_US","og_type":"article","og_title":"TenNor Therapeutics Raises $71M in Hong Kong IPO \u2013 Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections","og_description":"TenNor Therapeutics (Suzhou) Limited completed its initial public offering (IPO) on the Hong Kong Stock Exchange, pricing 8,280,550 shares at HKD 75.7 (USD 9.66) per share. The company expects to generate net proceeds of HKD 557.8 million (USD 71.22 million) to advance its antimicrobial pipeline toward commercialization.","og_url":"https:\/\/flcube.com\/?p=65299","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-14T06:28:42+00:00","article_modified_time":"2026-05-14T06:28:43+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1403.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65299#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65299"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"TenNor Therapeutics Raises $71M in Hong Kong IPO \u2013 Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections","datePublished":"2026-05-14T06:28:42+00:00","dateModified":"2026-05-14T06:28:43+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65299"},"wordCount":463,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=65299#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1403.webp","keywords":["IPO","TenNor Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65299#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65299","url":"https:\/\/flcube.com\/?p=65299","name":"TenNor Therapeutics Raises $71M in Hong Kong IPO \u2013 Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=65299#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=65299#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1403.webp","datePublished":"2026-05-14T06:28:42+00:00","dateModified":"2026-05-14T06:28:43+00:00","description":"TenNor Therapeutics (Suzhou) Limited completed its initial public offering (IPO) on the Hong Kong Stock Exchange, pricing 8,280,550 shares at HKD 75.7 (USD 9.66) per share. The company expects to generate net proceeds of HKD 557.8 million (USD 71.22 million) to advance its antimicrobial pipeline toward commercialization.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65299#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65299"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=65299#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1403.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1403.webp","width":1080,"height":608,"caption":"TenNor Therapeutics Raises $71M in Hong Kong IPO \u2013 Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65299#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"TenNor Therapeutics Raises $71M in Hong Kong IPO \u2013 Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1403.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65299","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65299"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65299\/revisions"}],"predecessor-version":[{"id":65303,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65299\/revisions\/65303"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/65301"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65299"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65299"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65299"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}